Multicomponent lifestyle intervention
Intervention1 paper2 findings
C · W · M · H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.
Company ties: findings with an author at a company, or from a paper that declares the maker’s interest.
- Human trial1
Outcomes
1Mobility disability
no changein humans1HR 1.06
1 study
Mobility disability
no changein humans1HR 1.06
Multicomponent lifestyle intervention has no effect on mobility disability in humans (HR 1.06, 95% CI 0.65-1.71).
Human trialin benzodiazepine users with SPPB scores 3 to 7physical exercise and nutritional counselling
Does the use of benzodiazepine influence the effectiveness of lifestyle intervention? Secondary analysis from the Sarcopenia and Physical fRailty iN older people strategies (SPRINTT) trial · Age and ageing · 3 Aug 2026
Associations
1Mobility disability
downin humans1HR 0.8
1 study
Mobility disability
downin humans1HR 0.8
Multicomponent lifestyle intervention lowers the risk of mobility disability in humans (HR 0.80, 95% CI 0.66-0.97).
Human trialin non-users of benzodiazepines with SPPB scores 3 to 7physical exercise and nutritional counselling
Does the use of benzodiazepine influence the effectiveness of lifestyle intervention? Secondary analysis from the Sarcopenia and Physical fRailty iN older people strategies (SPRINTT) trial · Age and ageing · 3 Aug 2026